| Linagliptin and Metformin Hydrochloride | Boehringer Ingelheim | ||
| 2.5 mg/1000 mg, 5 mg/1000 mg; Tablet ER |
Less Than $1000 mn
|
||
| None | None | ||
|
More Than 5
|
Less Than 5
|
||
| None | None | ||
| Jentadueto XR (linagliptin and metformin hydrochloride extended-release) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both linagliptin and metformin is appropriate. | |||
|
Yes
| |||
| Jentadueto XR | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| *** **** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| *** ****** | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* | *** ********* |
| ****** ****** ***** ** ****** ******** | ****** ****** ** ******* ******* ********* ** ********* **********-******* **** ****** ***** | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | *-[*-*****-*********-*-**]-*********, *** *********** ******* *** ***** *** ** ************** ************ | **** ** ***-** ********** | ******* *** *** *********** ** ****** *-(*-**************-*-**)-********* | ***-** ********* ******** **** * ******* ************ *****, ******* ********** **** ************, ***** *** *** ******* *** ***** *********** | **** ** *** ** ********** | ***-** ********* ******** **** * ******* ************ *****, ******* ********** **** ************, ***** *** *** ******* *** ***** *********** | ************** *********** *** **** ******* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| *** **** | *** \ ** | -**- | *** ********* | ********* ******** | ***** *** **** (******** ******) |
| *** ****** | ** \ ** | -**- | *** ********* | ********* ******** | ***** *** **** (******** ******) |
Download ParaIV Report
| Drug Name | Generic Name | Dosage | Route of Administration | Probable FTF | Known Para IV Filers | Other ANDA Developers |
|---|